Search results for " stroke"

showing 10 items of 328 documents

Electrophysiology and neuronal integrity following systemic arterial hypotension in a rat model of unilateral carotid artery occlusion.

2007

Patients with carotid artery stenosis may be particularly susceptible to hypotension-associated cerebral ischemia and subsequent neurological sequelae. Measuring somatosensory evoked potentials (SEP), electroencephalogram (EEG), direct current (DC) potential, and histology, we compared the temporal evolution of cortical functional perturbations as well as neuronal integrity in a model of unilateral carotid artery occlusion and systemic hypobaric hypotension (HH) at the lower limit of cerebral blood flow autoregulation (50 mm Hg). Serial measurements of EEG power spectra as well as SEP-amplitudes and latencies of N10.3 were performed before, during, and up to 60 min after 30 min-HH (n=7) or …

MaleTime FactorsIschemiaWatershed strokeFunctional LateralityReaction TimeMedicineAnimalsCarotid StenosisRats WistarMolecular BiologyStrokeNeuronsAnalysis of VarianceCell Deathbusiness.industryGeneral NeuroscienceSpectrum AnalysisCortical Spreading DepressionElectroencephalographymedicine.diseaseRatsElectrophysiologyDisease Models Animalmedicine.anatomical_structureCerebral blood flowCerebral cortexSomatosensory evoked potentialCortical spreading depressionCarotid artery occlusionAnesthesiaNeurology (clinical)HypotensionbusinessDevelopmental BiologyBrain research
researchProduct

Incremental predictive value of mean platelet volume/platelet count ratio in in-hospital stroke after acute myocardial infarction.

2017

IF 2.558; International audience; Stroke is a serious complication after acute myocardial infarction (AMI) and is associated with an increased risk of death. Though the pathophysiological mechanisms are not exactly known, increased inflammation and platelet reactivity could play an important role in the occurrence of stroke during AMI. We aimed to investigate the relationship between both mean platelet volume (MPV), a parameter of platelet function, and C-reactive protein (CRP) and the occurrence of in-hospital ischemic stroke (IHS) after AMI. Data were obtained from a French regional survey for AMI that included 5976 patients admitted to an intensive care unit (ICU) between 2001 and 2010. …

MaleTime FactorsMESH : StrokeMyocardial InfarctionMESH : AgedMESH: ComorbidityComorbidityMESH: Hospitalization030204 cardiovascular system & hematologyMESH : Platelet Countlaw.inventionMESH: Proportional Hazards Models0302 clinical medicineMESH: Aged 80 and overRisk FactorslawMESH: Risk FactorsOdds Ratio[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleMyocardial infarctionMESH : BiomarkersStrokeMESH: Blood PlateletsAged 80 and overMESH: AgedEjection fractionMESH: Middle AgedMESH : PrognosisbiologyMESH : Mean Platelet Volume[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineMiddle AgedPrognosisIntensive care unitstrokeMESH : Risk Factors3. Good healthHospitalizationMESH: Myocardial Infarctionrisk factorplateletsMESH : ComorbidityCardiologyMESH : HospitalizationFemaleMean Platelet VolumeMESH : Time FactorsBlood Plateletsmedicine.medical_specialtyMESH : Male[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAcute myocardial infarctionMESH: PrognosisMESH: StrokeC-reactive protein03 medical and health sciencesInternal medicinemedicineHumansMESH : Middle AgedMESH: Platelet Countcardiovascular diseasesRisk factorMean platelet volumeMESH : Aged 80 and overSurvival analysisAgedProportional Hazards ModelsMESH: HumansPlatelet Countbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyC-reactive proteinMESH: Time FactorsMESH : HumansMESH : Blood Plateletsmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Odds RatioMESH: MaleMESH: Mean Platelet Volumebiology.proteinMESH: BiomarkersMESH : Odds RatioMESH : Myocardial InfarctionbusinessMESH: FemaleBiomarkers030217 neurology & neurosurgery
researchProduct

Papillary muscle relocation in conjunction with valve annuloplasty improve repair results in severe ischemic mitral regurgitation

2012

OBJECTIVE: The incidence of recurrent mitral regurgitation (MR) after restrictive annuloplasty (RA) was 5% to 20% in several reports. There are many opinions in favor of adding subvalvular procedures to RA to reduce the tenting forces and improve the repair results. METHODS: From March 2003 to May 2010, 55 patients with severe ischemic MR who had undergone papillary muscle (PPM) relocation in conjunction with mitral annuloplasty in our institutions were enrolled. The patients were matched 1:1 with those who underwent isolated RA using the propensity score. The mean left ventricular ejection fraction was 42% ± 6%. The mean tenting area and coaptation depth was 3.2 ± 0.6 cm(2) and 1.3 ± 0.2 c…

MaleTime FactorsMitral Valve AnnuloplastyLeftMyocardial IschemiaKaplan-Meier EstimateSeverity of Illness IndexVentricular Function LeftPapillary muscle annuloplasty mitral regurgitationPostoperative ComplicationsRisk FactorsMitral valve annuloplastyAged; Chi-Square Distribution; Disease-Free Survival; Female; Hospital Mortality; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Matched-Pair Analysis; Middle Aged; Mitral Valve Insufficiency; Myocardial Ischemia; Papillary Muscles; Postoperative Complications; Propensity Score; Proportional Hazards Models; Risk Assessment; Risk Factors; Secondary Prevention; Severity of Illness Index; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function Left; Mitral Valve AnnuloplastySecondary PreventionClinical endpointVentricular FunctionHospital MortalityMyocardial infarctionEjection fractionIncidence (epidemiology)Mitral Valve InsufficiencyMiddle AgedPapillary MusclesTreatment Outcomemedicine.anatomical_structureItalyCardiologyFemaleCardiology and Cardiovascular MedicinePulmonary and Respiratory Medicinemedicine.medical_specialtyMatched-Pair AnalysisRisk AssessmentDisease-Free SurvivalInternal medicinemedicineHumansPropensity ScorePapillary muscleAgedProportional Hazards ModelsMitral regurgitationChi-Square Distributionbusiness.industryStroke VolumeSettore MED/23 - Chirurgia Cardiacamedicine.diseaseSurgeryLogistic ModelsPropensity score matchingSurgerybusiness
researchProduct

Non-office-hours admission affects intravenous thrombolysis treatment times and clinical outcome

2018

In patients treated with intravenous thrombolysis (IVT), an unfavourable ‘non-office-hours effect’ on door-to-needle time (DNT) and clinical outcome has been suggested. This effect has been attributed to a number of factors, mostly related to either less efficient logistics or less (experienced) staffing during non-office hours (NH). These factors could result in longer DNTs and more protocol violations and thus in worse clinical outcome. On the other hand, one could also argue that the workload during NH is lower, which could result in less time delays in the various diagnostic processes and thus in better clinical outcome. Our hypothesis is that admission during NH has a negative effect o…

MaleTime delaysmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentOutcome (game theory)Time-to-TreatmentCohort Studies03 medical and health sciences0302 clinical medicinePatient AdmissionModified Rankin ScaleIschaemic strokemedicineHumansThrombolytic Therapy030212 general & internal medicineStrokeAgedAged 80 and overbusiness.industryThrombolysisMiddle Agedmedicine.diseasestroke3. Good healthMechanical thrombectomyPsychiatry and Mental healthTreatment OutcomeEmergency medicineCohortPhysical therapySurgeryFemaleNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology, neurosurgery, and psychiatry
researchProduct

Local Delivery of Nimodipine by Prolonged-Release Microparticles—Feasibility, Effectiveness and Dose-Finding in Experimental Subarachnoid Hemorrhage

2012

Background and purposeTo investigate the effect of locally applied nimodipine prolonged-release microparticles on angiographic vasospasm and secondary brain injury after experimental subarachnoid hemorrhage (SAH).Methods70 male Wistar rats were categorized into three groups: 1) sham operated animals (control), 2) animals with SAH only (control) and the 3) treatment group. SAH was induced using the double hemorrhage model. The treatment group received different concentrations (20%, 30% or 40%) of nimodipine microparticles. Angiographic vasospasm was assessed 5 days later using digital subtraction angiography (DSA). Histological analysis of frozen sections was performed using H&E-staining as …

MaleVasodilator AgentsGene ExpressionPolylactic Acid-Polyglycolic Acid CopolymerVasospasm IntracranialDrug DistributionMultidisciplinarymedicine.diagnostic_testMicrofilament ProteinsQRBrainIntracranial ArteryVasospasmAnimal ModelsImmunohistochemistryHemorrhagic StrokeNeurologyAnesthesiaInjections IntravenousToxicityMedicinemedicine.symptomMicrotubule-Associated ProteinsResearch Articlemedicine.drugDrugs and DevicesDrug Research and DevelopmentSubarachnoid hemorrhageCerebrovascular DiseasesScienceNeurosurgeryBrain damageDrug Administration ScheduleModel OrganismsmedicineAnimalsPharmacokineticsLactic Acidcardiovascular diseasesRats WistarBiologyNimodipineDose-Response Relationship Drugbusiness.industryCalcium-Binding ProteinsAngiography Digital SubtractionDigital subtraction angiographySubarachnoid Hemorrhagemedicine.diseaseRatsnervous system diseasesDelayed-Action PreparationsAngiographyRatNimodipineSurgerybusinessPolyglycolic AcidPLoS ONE
researchProduct

Hyperexcitability of parietal-motor functional connections in the intact left-hemisphere of patients with neglect

2008

Hemispatial neglect is common after unilateral brain damage, particularly to perisylvian structures in the right-hemisphere (RH). In this disabling syndrome, behaviour and awareness are biased away from the contralesional side of space towards the ipsilesional side. Theoretical accounts of this in terms of hemispheric rivalry have speculated that the intact left-hemisphere (LH) may become hyper-excitable after a RH lesion, due to release of inhibition from the damaged hemisphere. We tested this directly using a novel twin-coil transcranial magnetic stimulation (TMS) approach to measure excitability within the intact LH of neglect patients. This involved applying a conditioning TMS pulse ove…

Malegenetic structuresmedicine.medical_treatmentHumans; Stroke; Aged; Parietal Lobe; Motor Cortex; Evoked Potentials Motor; Adult; Neural Pathways; Middle Aged; Psychomotor Performance; Transcranial Magnetic Stimulation; Female; Functional Laterality; Male; Perceptual DisordersParietal cortexFunctional LateralityParietal LobeNeural PathwaysrTMSNeglect syndromeEvoked Potentialsmedia_commonConnectivityneglectParietal lobeMotor CortexCortical excitabilityMiddle AgedTranscranial Magnetic StimulationStrokemedicine.anatomical_structureMotorSettore MED/26 - NeurologiaFemalemedicine.symptomPerceptual DisorderPsychologyMotor cortexHumanAdultmedia_common.quotation_subjectPosterior parietal cortexArticleLateralization of brain functionrehabilitationNeglectNOPerceptual DisordersNeural PathwaymedicineHumansAgedHemispatial neglectEvoked Potentials MotorTranscranial magnetic stimulationneglect syndrome; transcranial magnetic stimulation; connectivity; rTMS; parietal cortex; cortical excitabilityUnilateral neglectTMSNeurology (clinical)NeurosciencePsychomotor Performance
researchProduct

''Circulating and Brain BDNF Levels in Stroke Rats. Relevance to Clinical Studies''

2011

International audience; ''Background: Whereas brain-derived neurotrophic factor (BDNF) levels are measured in the brain in animal models of stroke, neurotrophin levels in stroke patients are measured in plasma or serum samples. The present study was designed to investigate the meaning of circulating BDNF levels in stroke patients. Methods and Results: Unilateral ischemic stroke was induced in rats by the injection of various numbers of microspheres into the carotid circulation in order to mimic the different degrees of stroke severity observed in stroke patients. Blood was serially collected from the jugular vein before and after (4 h, 24 h and 8 d) embolization and the whole brains were co…

Malelcsh:MedicineEDEMA''CardiovascularBiochemistry0302 clinical medicineNeurotrophic factorsJugular veinEdemaBlood plasmaNeurobiology of Disease and RegenerationMedicineHippocampus (mythology)Plateletlcsh:ScienceStroke0303 health sciencesMultidisciplinary''NEUROTROPHIC FACTORbiologyBrainNeurochemistryAnimal ModelsRECOVERYDEPRESSIONPLATELETSStrokeISCHEMIC-STROKENeurologyOrgan SpecificityAnesthesia[ SCCO.NEUR ] Cognitive science/NeuroscienceMedicinemedicine.symptomNeurotrophinResearch Articlemedicine.medical_specialtyCerebrovascular DiseasesImmunologyMETABOLISM03 medical and health sciencesModel OrganismsInternal medicineAnimalsHumanscardiovascular diseasesRats WistarImmunoassaysBiology030304 developmental biologyIschemic Strokebusiness.industryBrain-Derived Neurotrophic Factor[SCCO.NEUR]Cognitive science/Neurosciencelcsh:REDEMAmedicine.diseaseENDOTHELIAL-CELLSRatsEndocrinologynervous systemMARKERbiology.proteinImmunologic TechniquesRatlcsh:QClinical Immunologybusiness030217 neurology & neurosurgeryNeuroscienceNEUROTROPHIC FACTOR
researchProduct

Cryptogenic stroke and atrial fibrillation in a real-world population: the role of insertable cardiac monitors

2020

AbstractThe incidence of atrial fibrillation (AF) in cryptogenic stroke (CS) patients has been studied in carefully controlled clinical trials, but real-world data are limited. We investigated the incidence of AF in clinical practice among CS patients with an insertable cardiac monitor (ICM) placed for AF detection. Patients with CS admitted to our Stroke Unit were included in the study; they received an ICM and were monitored for up to 3 years for AF detection. All detected AF episodes of at least 120 sec were considered. From March 2016 to March 2019, 58 patients (mean age 68.1 ± 9.3 years, 67% male) received an ICM to detect AF after a CS. No patients were lost to follow-up. AF was detec…

Malelcsh:MedicineKaplan-Meier Estimate030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk Factorslcsh:ScienceStrokeMultidisciplinaryIncidence (epidemiology)QRNeuro-vascular interactionsAtrial fibrillationICM deviceStrokeTreatment OutcomeCardiologyMedicineFemaleSettore MED/26 - Neurologiamedicine.symptommedicine.medical_specialtyScienceNeurophysiologyCryptogenic strokeAsymptomaticArticleProsthesis ImplantationLoop recorder03 medical and health sciencesInternal medicinemedicineHumansAgedMonitoring Physiologicbusiness.industrylcsh:RAnticoagulantsmedicine.diseaseAtrial fibrillationClinical trialCryptogenic strokeAnticoagulant therapyElectrocardiography AmbulatoryCardiac monitorslcsh:Qbusiness030217 neurology & neurosurgeryFollow-Up StudiesScientific Reports
researchProduct

Impact of atrial fibrillation/flutter on the in-hospital mortality of ischemic stroke patients.

2020

Stroke is the second leading cause of death worldwide. Ischemic strokes, which are caused by atrial fibrillation/flutter (AF), may be more devastating than those that occur without AF.The purpose of this study was to investigate the impact of AF on adverse events in hospitalized ischemic stroke patients and to estimate the elevated impact of AF on the occurrence of these adverse events.The nationwide German inpatient sample of the years 2005-2015 was used for this analysis. Ischemic stroke patients were identified by ICD code I63 and stratified by AF. Logistic regression models were used to investigate the impact of AF on adverse in-hospital events and adjusted for age, sex, and comorbiditi…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyLogistic regressionBrain Ischemia03 medical and health sciences0302 clinical medicineRisk FactorsPhysiology (medical)Internal medicineCause of DeathGermanyCase fatality rateAtrial FibrillationmedicineHumanscardiovascular diseases030212 general & internal medicineHospital MortalityAdverse effectStrokeCause of deathAgedRetrospective StudiesAged 80 and overInpatientsAtrial fibrillation flutterbusiness.industryAtrial fibrillationMiddle Agedmedicine.diseasePrognosisSurvival RateAtrial FlutterIschemic strokeCardiologyFemaleCardiology and Cardiovascular MedicinebusinessHeart rhythm
researchProduct

Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.

2022

Purpose Only a few studies are available on dose-related effects of sacubitril/valsartan (angiotensin receptor neprilysin inhibition (ARNI)) in real-life patients with heart failure and reduced ejection fraction (HFrEF). We sought to investigate clinical and functional effects in real-life HFrEF patients receiving ARNI at a different cumulative dose. Methods This was an observational study in consecutive outpatients admitted for HFrEF from October 2017 to June 2019. The PARADIGM criteria were needed for enrolment. ARNI was uptitrated according to blood pressure, drug tolerability, renal function and kaliemia. At least 10-month follow-up was required in each patient. Clinical assessment, Kan…

Malemedicine.medical_specialtyARNIBlood PressureWalk TestComorbiditySacubitrilVentricular Function LeftAngiotensin Receptor AntagonistsInternal medicinemedicine6-min walking test Aged Aminobutyrates Angiotensin Receptor Antagonists ARNI Biphenyl Compounds Blood Pressure Comorbidity Dose-Response Relationship Drug Drug Combinations Echocardiography Female Heart failure Humans Left ventricular function Male Middle Aged Prospective Studies Sacubitril/valsartan Stroke Volume Valsartan Ventricular Function Left Walk TestHumansPharmacology (medical)Sacubitril/valsartanProspective Studies6-min walking testAgedPharmacologyHeart FailureEjection fractionDose-Response Relationship DrugCumulative dosebusiness.industryAminobutyratesLeft ventricular functionBiphenyl CompoundsStroke VolumeGeneral MedicineMiddle Agedmedicine.diseaseClinical TrialARNI heart failure left ventricular function 6-minutes walking test Sacubitril/valsartan.Drug CombinationsBlood pressureTolerabilityValsartanEchocardiographyHeart failureCardiologyValsartanFemalebusinessSacubitril Valsartanmedicine.drugEuropean journal of clinical pharmacology
researchProduct